Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 4/20 | 0.37 |
| ▸ | F3 | P13726 | 4/20 | 0.37 |
| ▸ | F2 | P00734 | 3/20 | 0.37 |
| ▸ | F10 | P00742 | 3/20 | 0.37 |
| ▸ | F11 | P03951 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17705257 | 1.00 | F7 (0.37) | F7F3F2F10F11 | |
| SCHEMBL17700716 | 0.94 | F2 (0.38) | F7F3F2F10F11 | |
| SCHEMBL17700626 | 0.94 | F2 (0.38) | F7F3F2F10F11 | |
| SCHEMBL17700629 | 0.94 | F2 (0.38) | F7F3F2F10F11 | |
| SCHEMBL17700691 | 0.93 | F2 (0.35) | F7F3F2F10F11 | |
| SCHEMBL17700693 | 0.93 | F2 (0.35) | F7F3F2F10F11 | |
| SCHEMBL17700745 | 0.93 | F2 (0.35) | F7F3F2F10F11 | |
| SCHEMBL17705236 | 0.90 | F7 (0.37) | F7F3F2F10F11 | |
| SCHEMBL16307008 | 0.86 | F2 (0.38) | F7F3F2F10F11 | |
| SCHEMBL16307069 | 0.86 | F2 (0.38) | F7F3F2F10F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657006-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | F7, F12, F5 | F7 1/4885F3 14/4885F2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.